Company Overview
Snapshot
Founded in September 2018 by Kfir Schreiber, Thrasyvoulos (Thras), and Joseph Jacobson, DeepCure operates with 11–50 employees. The company has secured funding across two rounds from three investors, with Morningside Venture Investments leading a round. In January 2023, DeepCure collaborated with Biosero to establish a fully automated, AI-powered chemistry synthesis platform.
Business overview
DeepCure is a Health Tech & Life Sciences company that develops an AI platform for drug discovery. Its core technology leverages deep learning algorithms, cloud computing infrastructure, and a proprietary database of over 1 trillion chemistries to identify novel drug candidates. The platform, including its MolDB molecular database, is designed to search vast chemical spaces and expand to 1 quintillion molecules, enabling the discovery of candidates not found in traditional screening libraries. DeepCure primarily serves the biotechnology and pharmaceutical industries within the life sciences sector.
Strategic signal
In January 2023, DeepCure announced a collaboration with Biosero to create a fully automated, AI-powered chemistry synthesis platform. This partnership is significant as it indicates DeepCure's strategic move towards integrating its AI drug discovery capabilities with automated laboratory systems, potentially accelerating the translation of AI-identified drug candidates into tangible compounds. For investors, this signals a commitment to enhancing operational efficiency and scalability in drug development, reducing time-to-market, and validating the practical application of their AI technology in a real-world lab setting.
Log in to access full profile ›Company Intelligence Q&A
- What is DeepCure's primary focus?
- DeepCure's primary focus is AI-driven drug discovery, utilizing deep learning algorithms and a vast proprietary molecular database to identify novel drug candidates.
- When was DeepCure founded and by whom?
- DeepCure was founded in September 2018 by Kfir Schreiber, Thrasyvoulos (Thras), and Joseph Jacobson.
- What was a significant recent collaboration for DeepCure?
- In January 2023, DeepCure collaborated with Biosero to establish a fully automated, AI-powered chemistry synthesis platform.
- Who was a key appointment to DeepCure's leadership team?
- In April 2022, DeepCure appointed Dr. Han Lim as its Chief Business Officer, bringing extensive experience in business development and strategic partnerships within the pharmaceutical industry.
- Which investors participated in DeepCure's November 2021 funding round?
- In November 2021, DeepCure closed a Series A funding round led by Morningside Venture Investments, with participation from.